Product Reports Resources Pricing Login Book a demo

Kymera Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020

A biotechnology company pioneering a transformative new approach to treating previously untreatable diseases

Valuation $7.92B
Revenue $85M
Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Talent graph

Kymera Therapeutics's talent

Book a demo to see the people
Employees mapped 306 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

12 investors on Kymera Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Lilly Ventures
Amgen Ventures
Atlas Venture
Series B+ 9 investors entered at this stage
Rock Springs Capital
Wellington Management
6 Dimensions Capital
Bain Capital Life Sciences
Janus Henderson Investors
BVF Partners
Bessemer Venture Partners
Redmile Group
BlackRock

Kymera Therapeutics mafia

Startups founded by Kymera Therapeutics alumni

Former Kymera Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Fortitude BiomedicinesEst. 2025
Jesse ChenUnited States
Signal score91
PAQ TherapeuticsEst. 2020
NJNan JiUnited States
Signal score81
Orbital TherapeuticsEst. 2022
John MaraganoreUnited States
Signal score62
Parthenon TherapeuticsEst. 2019
LALaurent AudolyUnited States
Signal score61

Book a demo to explore the full alumni network →

Global footprint

Where Kymera Therapeutics has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States98.5%
🇨🇦 Canada1%
🇲🇾 Malaysia0.5%
3 countries shown
Web traffic by country
22K monthly visits
across markets
🇺🇸 United States73.6%
🇬🇧 United Kingdom11.4%
🇮🇳 India7.7%
🇯🇵 Japan4.1%
🇫🇷 France2.3%
Top 5 markets shown

Patent intelligence

$28M patent portfolio · 98 active families

Estimated portfolio value
$28M
0.36% of market cap · 11.8× smaller than top peer Translate Bio ($336M)
98 active patent families
Where Kymera Therapeutics innovates BiochemistryCarcinosisCombinatorial chemistryDiseaseMedicinal chemistry

Where Kymera Therapeutics concentrates vs peers

Each axis is a top-10 topic across Kymera Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Kymera Therapeutics

An AI-synthesized read of the highest-engagement posts about Kymera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kymera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles